Market Signal Briefing

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017,
aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy,
our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a
rigorous Review Methodology when evaluating exchanges and tools. From emerging
blockchain projects and coin launches to industry events and technical developments, we cover
all facets of the digital asset space with unwavering commitment to timely, relevant information.

The SUI Network is gaining traction thanks to recent developments in its ecosystem. This includes the success of Astros’ Perp DEX, which surpassed $100 million in trading volume a week after going live. The project also announced a native stablecoin called USDsui.

Astros Perp DEX Hits Over $100 Million in Trading Volume
In late October, Astros launched its perpetual DEX on the SUI Network. Within days, the cumulative trading volume of its platform surpassed $100 million. This would indicate strong user adoption.

To encourage participation, Astros implemented the “Ores Lucky Draw” every day, based on users’ trading activity. These Astros Ores tokens are one of the main components in rewarding users within the platform. They serve as a ticket for future ecosystem benefits and airdrops.

With Astros’ launch, SUI is competing in DeFi’s most lucrative domain. That sector recently hit $1 trillion in monthly trading volume like Aster saw incredible growth. Perp DEXs make up more than a quarter of the global derivatives market.

“Perp DEXs have become the ultimate litmus test for a blockchain’s ability to support real financial infrastructure,” said Jerry Liu, founder of Astros. “Sui’s performance advantage gives us the foundation to compete at the highest level.”

Built natively on SUI Network, Astros enjoys direct integration with NAVI Protocol’s lending pool worth US$1 billion. According to Liu, the Astros Perp DEX is changing DeFi’s trajectory. Unlike earlier iterations of decentralized finance that operated through isolated lending or swapping protocols,

Major crypto wallets have already partnered with the Astros team, including OKX, Binance, KuCoin, and Gate.io, for broad accessibility to users in the SUI ecosystem.

SUI Network Launches Native Stablecoin, USDsui
In a blog post published earlier, SUI Network announced the release of its first native stablecoin, USDsui. It was developed in collaboration with Bridge, the company which Stripe backs. USDsui will be important for Sui’s on-chain economy. It would offer a compliant stablecoin to developers and users integrated throughout DeFi protocols.

Sui unveils USDsui, a native stablecoin issued by @Stablecoin, a @Stripe company.

Fiat-backed, GENIUS-ready, and yield-sharing – USDsui anchors the Sui economy, powering payments, DeFi, and real-world use cases across the network. pic.twitter.com/ehI7txlODL

— Sui (@SuiNetwork) November 12, 2025

Built on Bridge’s Open Issuance platform, USDsui benefits from enterprise-grade infrastructure. It is designed for payments, cross-border remittances, and peer-to-peer transactions.

“With this launch, Sui’s digital assets are connected with global commerce and fintech rails, making Sui a leading player for the next phase of on-chain economic activity,” said Adeniyi Abiodun, Co-Founder and Chief Product Officer at Mysten Labs.

Bridge CEO Zach Abrams added that Open Issuance “removes the complexity and long timelines associated with stablecoin creation.” It would let networks such as Sui scale rapidly with robust, regulatory-aligned stable assets. The platform joins Hyperliquid, which also launched its own stablecoin in September.

Between August and September 2025 alone, the network processed approximately $2.6 billion in TVL and $412 billion in stablecoin transaction volume. The platform has become one of the most active ecosystems for digital asset settlement.

Story HighlightsThe PENDLE price today is  $ 2.69368698Pendle Coin’s price could hit a maximum of $7.65 in 2025.Pendle coin price with a potential uptrend may peak at a maximum of $80.21 by 2030.Pendle is a DeFi protocol that allows the tokenization and trading of future yield, giving its users more flexibility in managing yield-bearing assets. It features a unique AMM designed for assets with time constraints, allowing innovative strategies within decentralized finance. 

PENDLE tokens are actively traded across major cryptocurrency exchange platforms like Binance, Gate.io, and MEXC, offering strong liquidity. Pendle’s unique approach has sparked curiosity among investors, leading to interest in Pendle Price Forecast. This Pendle Price Prediction 2025, 2026-2030 will be your go-to if you are keen on sacking some tokens.

Pendle Price TodayCryptocurrencyPendleTokenPENDLEPrice$2.6937 -0.98% Market Cap$ 448,242,532.9524h Volume$ 52,320,024.3204Circulating Supply166,404,833.6162Total Supply281,527,448.4585All-Time High$ 7.5171 on 11 April 2024All-Time Low$ 0.0335 on 09 November 2022Pendle Price ChartTechnical AnalysisPendle (PENDLE) is trading at $2.672, hovering just below the 20-period SMA at $2.762.

Key Support: $2.556 (lower Bollinger Band), with price recently testing this level.Resistance: $2.762 (20 SMA), followed by $2.969 (upper Bollinger Band).Indicators: RSI at 45.61 signals weak bearish momentum, with the market slightly below neutral.Pendle Short-Term Price PredictionPendle Crypto Price Prediction 2025The kickstart of a bull run in the DeFi sector will give Pendle the much-needed push to its yearly high of $7.65. On the flipside, if the DeFi sector goes unnoticed during the bull season, its price might plunge to $1.91. Considering the buying and selling pressures, the average price might be around $4.78. 

YearPotential LowPotential AveragePotential High2025$1.91$4.78$7.65Are you wondering about the long-term price prospects of BTC? Read our latest Bitcoin Price Prediction today!

Pendle Coin Mid-Term Price TargetsYearPotential Low ($)Potential Average ($)Potential High ($)2026$3.06$7.65$12.242027$4.90$12.24$19.582028$7.84$19.58$31.332029$12.55$31.33$50.132030$20.08$50.13$80.21Pendle Crypto Price Forecast 2026The PENDLE crypto prediction for 2026 could range between $3.06 to $12.24. Considering the buying and selling pressure, the average price could be around $7.65 for that year.

PENDLE Price Prediction 2027In 2027, the Pendle cryptocurrency value could reach a maximum trading value of $19.58 with a potential low of $4.90. Considering the market sentiments, the average price could land at around $12.24.

Pendle Long-Term Price PredictionYearPotential Low ($)Potential Average ($)Potential High ($)2028$7.84$19.58$31.332029$12.55$31.33$50.132030$20.08$50.13$80.21PENDLE Price Projection 2028By the end of 2028, the value of the Pendle coin could hit a maximum of $31.33, with a potential low of $7.84. With this, the average price could land at around the $19.58 mark.

Pendle Price Analysis 2029Moving forward to 2029, the Pendle coin price may range between a peak of $50.13 and a low of $12.55, and a potential average value of around $31.33.

Pendle Coin Price Prediction 2030The Pendle price could claim a high of $80.21 by the year 2030. However, the altcoin could record a low of $20.08 and an average price of $50.13, if the crypto market turns bearish.

Considering stacking more ETH tokens before the altseason begins? Read CoinPedia’s Ethereum price prediction 2025, 2026 – 2030!

Market AnalysisFirm Name202520262030CoinCodex$ 4.90$ 3.45$ 8.53Mudrex$6.00$15$110MEXC$5.18$6.49$29.78*The aforementioned targets are the average targets set by the respective firms.

CoinPedia’s Pendle Price PredictionExpecting a bullish future, the Pendle price could claim a high of $7.65 in 2025. Contrarily, in bearish circumstances, this could result in this altcoin plummeting toward its annual low of $1.91.

YearPotential LowPotential AveragePotential High2025$1.91$4.78$7.65Also, read Binance coin price prediction 2025, 2026 – 2030!

FAQsWhat is the total supply of PENDLE?

The total supply of PENDLE is 281.52M tokens

Is PENDLE a good investment?

Yes, considering its strong fundamentals, PENDLE could be a great investment for the long term

What is the 2025 price prediction for Pendle?

According to the analysis done by our expert panel, the PENDLE price is expected to hit a maximum of $7.65 by the end of 2025.

What will the price of Pendle be by the end of 2030?

The price of 1 Pendle crypto could be as high as $80.21 by the end of 2030.

Disclaimer and Risk WarningThe price predictions in this article are based on the author's personal analysis and opinions. CoinPedia does not endorse or guarantee these views. Investors should conduct independent research before making any financial decisions.

XRP, the native cryptocurrency of the Ripple network, appears ready for another bullish wave after holding firm above the crucial $2.35 support level. Following a brief correction, the digital asset is regaining momentum as traders anticipate another upward push, potentially targeting the $2.60 zone in the coming days.

XRP Holds Ground After Minor Correction
After reaching a recent high near $2.58, XRP experienced a mild pullback, mirroring the broader correction seen in Bitcoin and Ethereum. The token dropped below the $2.55 and $2.50 resistance areas before finding solid buying interest around $2.32. This level has now become a key support zone, with bulls stepping in to prevent further losses.

The dip also brought the price below the 50% Fibonacci retracement level of the upward move from $2.24 to $2.58, signaling short-term weakness. However, the resilience of buyers around $2.32 suggests that the market remains optimistic about XRP’s medium-term outlook.

At the time of writing, XRP is trading close to $2.42 and the 100-hourly Simple Moving Average (SMA). This consolidation phase indicates that traders are waiting for a decisive breakout before committing to new positions.

Technical Indicators Hint at a Potential Upside
On the hourly chart, XRP/USD faces a bearish trend line resistance near the $2.43 mark, a level that has repeatedly capped upward movements. A successful break above this resistance could trigger a strong rally toward the $2.50 level, which remains the next significant obstacle for buyers.

If bulls manage to push past $2.50, the momentum could extend toward the $2.58 resistance zone, effectively retesting the previous local high. A sustained move above $2.58 might open the door for XRP to challenge $2.65 and potentially $2.72, which could act as the next major targets for traders eyeing continued upside.

Momentum indicators, such as the Relative Strength Index (RSI), are beginning to show signs of recovery after hovering near the neutral zone. This shift points to a potential change in sentiment as buyers slowly regain control.

Key Support Levels to Watch
In case of another downturn, initial support lies near $2.34, followed by a stronger base around $2.32. A clear move below this level could invalidate the current bullish setup and trigger a deeper correction. The next support level would then emerge near $2.25, marking a full retracement toward the previous swing zone.

Should selling pressure intensify, XRP might revisit the $2.20 support or even dip toward $2.12, although such a move currently appears less likely given the prevailing bullish sentiment across the broader crypto market.

Bulls Eye $2.50 Breakout for Next Leg Higher
The broader trend still favors buyers as long as XRP maintains its position above the $2.35–$2.32 range. A convincing breakout above $2.50 would likely attract fresh buying interest from traders and short-term speculators. This could push the token toward the upper resistance cluster between $2.58 and $2.65, where some profit-taking might occur before the next upward attempt.

Market analysts note that XRP’s performance has been relatively stable compared to other major altcoins, largely due to growing investor confidence following Ripple’s progress in regulatory clarity and institutional adoption. Continued accumulation near the $2.35 support reflects faith in the token’s long-term value proposition, especially among holders expecting renewed momentum toward the end of the year.

Broader Market Context
The recent recovery in XRP also aligns with the improved outlook for the broader cryptocurrency market. Bitcoin’s ability to stay above the $108,000 zone and Ethereum’s steady performance above $3,400 have contributed to a more positive sentiment across digital assets.

If these leading cryptocurrencies continue to stabilize, XRP could benefit from renewed investor confidence and capital inflows. Historical price patterns suggest that XRP often follows Bitcoin’s trend but tends to move more sharply once bullish momentum takes hold.

What Traders Should Expect Next
In the short term, traders will be watching the $2.43–$2.50 resistance range closely. A breakout above this zone could confirm a bullish reversal and pave the way for XRP to test $2.58 and $2.65 in the coming sessions. Conversely, a failure to break above resistance might keep the price in a consolidation range between $2.32 and $2.45 before the next decisive move.

As long as the $2.32 support holds, market structure remains positive, with the potential for another leg higher. However, a breakdown below this level could shift momentum in favor of sellers, bringing the price back toward $2.25 or even $2.20.

Outlook Remains Positive Above $2.35
Despite recent fluctuations, XRP’s overall market sentiment remains constructive. Technical signals, combined with strong buying interest at lower levels, suggest that the cryptocurrency could soon resume its upward trajectory. If momentum builds above $2.50, traders may see a move toward $2.60 and potentially higher targets by the end of the week.

For now, the bulls remain firmly in control as long as XRP stays above the $2.35 support zone. Investors will be watching closely to see if the token can break through its resistance barriers and reclaim its position as one of the best-performing large-cap assets in the market.

Post Views: 5

Crypto prices today are showing early signs of stabilization as the prolonged U.S. government shutdown comes to an end.

Summary

Crypto markets may recover after the 43-day U.S. government shutdown ended, though extreme fear still dominates sentiment.
Liquidity and institutional flows were heavily disrupted during the shutdown.
Temporary budget may ease near-term pressures, but persistent inflation could continue to weigh on crypto.

The total crypto market capitalization has fallen 0.6% over the past 24 hours but is edging higher. At press time, Bitcoin was down 1.4% to $101,843, Ethereum rose 0.5% to $3,465, XRP gained 2.8% to $2.46, and Solana fell 0.7% to $153.

Investor sentiment remains cautious. Extreme fear is indicated by the Crypto Fear & Greed Index, which fell nine points to 15, its lowest level since April. CoinGlass data shows that 24-hour liquidations rose 26% to $569 million while total open interest dropped 0.6% to $142 billion.

With an average relative strength index of 45, the crypto market may consolidate before making a significant move.

Temporary relief from the U.S. shutdown
On Nov. 12, the 43-day U.S. government shutdown came to an end after President Trump signed a temporary budget. The bill was approved by the House earlier in the day, reopening federal agencies and resuming the flow of economic data. By lowering uncertainty and enabling markets to regain some stability, this move might offer short-term respite.

Liquidity had been severely disrupted by the shutdown, which started on Oct. 1. Treasury repo rates rose 18–22 basis points as banks hoarded cash while federal agencies were closed. Additionally, the lack of important economic data increased market uncertainty. Due to the postponement of the October CPI, PPI, retail sales, and nonfarm payroll reports, the Federal Reserve was placed in a “data-dependent” hold.

Markets cut the odds of a December rate cut from 92% to 58% in just a few weeks. Bitcoin’s 30-day realized volatility spiked to 78%, the highest since the FTX collapse, making every headline a potential trigger for market swings.

Moreover, institutional flows stalled. New ETF approvals were delayed due to Securities and Exchange Commission staff furloughs, and risk appetite sharply declined. The correlation between cryptocurrency and the Nasdaq increased to 0.88, and institutions decreased their exposure as stocks wavered.

Lingering macro and market pressures
Despite the shutdown resolution, market and macro pressures remain. Momentum is still being slowed by recent liquidity shortages and waning interest in industries like tokenization and real-world assets. Stablecoins have stayed steady while other sectors, like AI and meme tokens, have seen sharp drops.

Bearish sentiment has also kept markets quiet, and open interest is still 20% below recent highs. The next funding deadline is Jan. 30, 2026, so the temporary budget only offers a temporary solution. According to analysts, long-term initiatives and pro-crypto laws might boost confidence, but short-term volatility is probably going to continue.

Crypto Journalist

Amin Ayan

Crypto Journalist

Amin Ayan

About Author

Amin Ayan is a crypto journalist with over four years of experience in the industry. He has contributed to leading publications such as Cryptonews, Investing.com, 99Bitcoins, and 24/7 Wall St. He has...

Last updated: 

November 13, 2025

A judge at the Dubai International Financial Centre (DIFC) has imposed a worldwide freeze on $456 million in assets tied to the alleged misappropriation of TrueUSD (TUSD) stablecoin reserves, a case linked to Tron founder Justin Sun’s earlier bailout of the token.

Key Takeaways:

A Dubai court has ordered a worldwide freeze on $456 million in assets linked to the alleged diversion of TrueUSD reserves.
The injunction targets Dubai-based Aria Commodities DMCC, which allegedly received the funds instead of the designated reserve account.
Tron founder Justin Sun previously covered the $456 million shortfall to protect TUSD holders.

H.E. Justice Michael Black KC of the DIFC Digital Economy Court ordered the continuation of both proprietary and worldwide injunctions against Dubai-based Aria Commodities DMCC, barring the firm from transferring or dealing with any assets up to the value of $456 million.

Dubai Judge Extends Global Freeze on $456M Linked to TrueUSD CaseThe order was issued in an amended judgment on October 17.

“I direct that the following injunctions shall remain continued until further order of the Court: a worldwide freezing injunction, prohibiting the First Defendant [Aria DMCC] from removing from Dubai any of its assets which are in Dubai up to the value of USD 456,000,000,” Justice Black declared in the ruling.

The decision follows a long-running dispute between Techteryx Ltd, the operator of the TrueUSD stablecoin, and several financial institutions, including Aria Commodities DMCC, Mashreq Bank PSC, Emirates NBD Bank PJSC, and Abu Dhabi Islamic Bank PJSC.

According to the case filings, Techteryx, which acquired TrueUSD in 2020, was unable to redeem a large portion of its US dollar reserves managed by First Digital Trust between 2022 and 2023.

Investigations revealed that the funds, instead of being held in the proper Cayman Islands-based reserve account, were allegedly redirected by First Digital Trust to Aria Commodities DMCC in Dubai.

Counsel for Techteryx, Al Tamimi & Co, stated that the reserves were originally custodied in Hong Kong, and between May 2021 and March 2022, around $468 million was said to have been invested in the Aria Commodity Finance Fund, though nearly $456 million was transferred directly to Aria Commodities DMCC.

The diverted funds gave rise to claims of breach of trust and knowing receipt, prompting the proprietary injunction and the subsequent global asset freeze.

Justin Sun, listed in the filings as an ultimate beneficial owner of Techteryx, previously announced a full bailout of all public TUSD holders, covering the $456 million shortfall allegedly caused by the diversion.

Justin Sun Vows Global Pursuit of $456M in Missing TrueUSD FundsIn a post on X, Sun praised the DIFC Court’s decision, noting that Techteryx continues to track and recover the missing funds.

Six months after our announcement to bail out all public holders of TUSD, where US$456m of US Dollar reserves were siphoned-off by a group of fraudsters involving ARIA group, First Digital Trust and Legacy Trust, among others, I am pleased to see that progress has been made in…

— H.E. Justin Sun 👨‍🚀 🌞 (@justinsuntron) November 13, 2025
“This serves as a strong notice to all persons knowingly involved in global scam operations of ARIA. You can run but you cannot hide; we will come after you wherever you are,” Sun wrote.

The DIFC Court’s injunctions will remain in effect until further orders are issued, as Techteryx pursues the restitution of the missing TUSD reserves.

Follow us on Google News

Hyperliquid reportedly took a bad debt of $4.9 million due to alleged POPCAT manipulation.Updated Nov 13, 2025, 6:49 a.m. Published Nov 13, 2025, 6:48 a.m.

Decentralized derivatives platform Hyperliquid suffered a $4.9 million loss Wednesday after a carefully orchestrated manipulation of the POPCAT token, according to data shared by blockchain sleuth Lookonchain.

The attacker withdrew $3 million in USDC from centralized exchange OKX, splitting it across 19 wallets to create a massive leveraged long position valued between $20 million and $30 million in POPCAT.

STORY CONTINUES BELOW

The attacker then placed $20 million buy order near $0.21, pulling in liquidity and pushing prices higher. Once the position was sufficiently inflated, the attacker abruptly pulled the buy orders, causing a crash in POPCAT prices, which led to cascading liquidations of leveraged positions, including the attacker’s own $3 million collateral, which was gone in seconds.

Hyperliquid’s community-owned liquidity vault (HLP), which acts as a safety net for liquidations, had to absorb the remaining losses after collateral was exhausted, leading to a bad debt of $4.9 million, deepening the impact on the leading perpetual focused decentralized exchange.

CoinDesk reached out to Hyperliquid for comment via X.

One market participant described the episode as "peak degen warfare."

"Someone torched 3M just to nuke liquidity and drag HLP into a 5M loss. Classic manufactured demand illusion followed by a flush. Nothing magical here. Just an attacker exploiting thin depth and automated LP absorption," the participant said on X.

More For You

OwlTing: Stablecoin Infrastructure for the Future

Oct 16, 2025

Stablecoin payment volumes have grown to $19.4B year-to-date in 2025. OwlTing aims to capture this market by developing payment infrastructure that processes transactions in seconds for fractions of a cent.

View Full Report

More For You

Tokyo Exchange Operator Mulls Limits on Digital Asset Treasury Firms: Report

1 hour ago

The operator is exploring stricter enforcement of listing rules and audits to protect investors.

What to know:

Japan Exchange Group is considering measures to limit the growth of companies hoarding digital tokens as treasury assets.The Tokyo Stock Exchange operator is exploring stricter enforcement of listing rules and audits to protect investors.Read full story

Bitcoin price rebounds off the ascending channel’s lower trendline, hinting at a possible bottom.NUPL revisits its April bottom level, where Bitcoin last launched a 53% rally.A thick cost-basis wall above $109,683 remains the level Bitcoin must clear to confirm a real launch from the bottom. Bitcoin price corrected almost 4% over the past 24 hours before rebounding above $102,100 at press time. Even with a 30-day loss near 9.7%, several market signals now line up in a way that suggests a possible Bitcoin bottom may be forming. And it might just help BTC move towards a new all-time high.

The structure is not confirmed yet, but the clustering of signals is stronger than in recent weeks.

Sponsored

Sponsored

Ascending Channel Support Meets a Fresh Bottom SignalBitcoin has traded inside an ascending channel since April. The lower trendline has acted as reliable support since early spring, and the latest bounce from this line on November 4 keeps the channel intact. When bottoms form inside rising structures, the channel floor is usually the first place where strength appears.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Trading Pattern Still Bullish: TradingViewAt the same time, NUPL — a metric that shows whether holders sit on unrealized profit or loss — has dropped to about 0.44. This is near the lowest zone since April 8, when NUPL touched 0.42 and marked the exact cycle bottom. After that, Bitcoin rallied from about $76,700 to above $116,900 by late May. That’s almost a 53% surge.

New Bitcoin Bottom Signal Flashes: GlassnodeNow, the same combination appears again: a bounce from the channel floor and NUPL returning to its historical bottom zone. That is why traders think a possible bottom is starting upward.

Sponsored

Sponsored

But just like someone looking up at a summit, Bitcoin now faces one strong ridge directly above — the level blocking the view.

Cost-Basis Heatmap Reveals the Level Blocking the Bitcoin Price BreakoutThe cost-basis heatmap shows where the largest pockets of BTC supply sit. These pockets often block upside moves because many holders react when the price returns to their entry levels. One of the strongest clusters now sits between $109,895 and $110,192, backed by 117,078 BTC. Other strong BTC clusters exist before that, but this zone has the deepest of colors, especially in the near term.

Key BTC Resistance Zone: GlassnodeThat zone also lines up with the 0.618 Fibonacci level on the Bitcoin price chart, at $109,683, one of the strongest technical resistance points. Until Bitcoin clears this band, the possible bottom cannot fully convert into a recovery. Every bounce under this level might eventually fail.

A daily close above $109,683 would be the first signal that the ridge is cracking. A stronger confirmation comes above $112,652, which aligns with the 0.786 Fibonacci area. Above that, Bitcoin can target $116,435 and even the previous peak near $126,301.

Bitcoin Price Analysis: TradingViewIf BTC price fails again and drops back to the channel floor, the pattern still holds. But if Bitcoin breaks below the lower trendline, the bottom setup gets invalidated. In that case, price could slide toward $98,758, or even lower, which would weaken the entire bottom hypothesis.

For now, the ascending channel, the fresh NUPL bottom zone, and the heatmap cluster all point to the same idea: a possible Bitcoin price bottom is staring at a peak — but one major level still blocks the view.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

After an impressive rally since early 2025, Solana (SOL) is now approaching a critical zone, both technically and psychologically.

Journalist

Posted: November 13, 2025

Key Takeaways
Will Solana bulls defend the $150 psychological support level?
They have successfully kept the bears at bay at the $150 level over the past week, but a price dip to $140 is imminent.

What price trend would follow this expected dip?
It would depend on Bitcoin’s ability to stay above $98k-$100k, but a bounce from $140 is possible.

Solana [SOL] has suffered a nearly 10% drawdown from the week’s high at $171.9, and was trading at $155 at the time of writing.

Neither its edge in the stablecoin market nor the high monthly revenue Solana generated has been enough to start a long-term uptrend.

Source: SOL/USDT on TradingView

On the 1-day chart, SOL had broken down from the symmetrical triangle pattern and lost control of the $180 support zone in the first week of November. Since then, the price has made a series of lower highs and lower lows, characteristic of a downtrend.

The OBV indicator also trended downward. This indicates that the decline was driven by sustained selling pressure rather than a temporary liquidity hunt.

The MFI agreed with the seller dominance and remained below 50, showing that the momentum was bearish, and selling pressure was prevalent.

The lower timeframes signaled a potential dip to $140 for SOL

Source: SOL/USDT on TradingView

On the 1-hour chart, the $145-$155 demand zone has been important since the 4th of November. At the time of writing, the same support zone was being retested.

With Bitcoin [BTC] also hovering at the $102k mark at the time of writing, it was likely that this demand zone would be lost if the wider market experienced another sell-off.

The technical indicators did not promise a bullish reversal. The OBV continued to decline, showing weak buying pressure even when the price bounced. The MFI was below 20, indicating oversold conditions.

The 1-month look-back period heatmap showed that a deeper price correction was highly likely. The $144 and $140 were key magnetic zones and relatively close to the price.

They would likely drag SOL prices lower before a bounce can occur. Overall, the short-term Solana price prediction is bearish.

A dip to $140 is likely in the coming days, and with liquidity extending to $120, traders should brace for continued bearish pressure.

Disclaimer: The information presented does not constitute financial, investment, trading, or other types of advice and is solely the writer’s opinion

Akashnath S is a Senior Journalist and Technical Analysis expert at AMBCrypto. He specializes in dissecting price action, identifying key market trends through advanced chart patterns, and forecasting both short-term and long-term asset trajectories.
His distinct analytical method is grounded in his academic training as a Chemical Engineer. This background provides him with a systematic, process-oriented approach to market data, enabling him to analyze the complex dynamics of financial markets with precision and objectivity.
Having actively covered the cryptocurrency space since the landmark 2017 market cycle, Akashnath possesses years of experience navigating both bull and bear markets. This seasoned perspective is critical to his insightful reporting on market volatility and evolution.
As an active market participant, Akashnath enhances his analysis with crucial, hands-on experience. This practical application of his technical skills ensures his insights are not merely theoretical, but are also relevant and actionable for an audience looking to understand and navigate trading opportunities. He is dedicated to educating readers on the nuances of technical analysis, empowering them with the knowledge to make more informed financial decisions.

Bitwise Chainlink ETF (CLNK) listed on DTCC, signaling readiness for institutional access.Retail LINK holders keep selling despite strong fundamental progress.Whales accumulate 4M+ LINK as exchange balances drop to multi-year lows.The Bitwise Chainlink ETF has been listed on the Depository Trust and Clearing Corporation (DTCC) platform under ticker CLNK. This move marks a key step toward institutional access to LINK.

Yet, on-chain data shows LINK holders have continued selling throughout the past month, even as institutional confidence grows.

Sponsored

Sponsored

Bitwise Chainlink ETF Listed on DTCCThe long-awaited Bitwise Chainlink ETF (CLNK) has been listed on the DTCC platform, marking a significant step toward institutional access to the LINK token.

The listing does not yet signify regulatory approval, but it indicates progress toward eventual trading readiness.

This listing is part of the standard clearing and settlement preparation process before a potential SEC approval.

However, DTCC’s integration with Chainlink’s CCIP and CRE suggests the project’s expanding role in financial infrastructure.

DTCC integration with CCIP and CRE. Source: Chainlink Ecosystem WebsiteSponsored

Sponsored

Chainlink Steps into the Fed’s CircleFurther strengthening its institutional credibility, Chainlink Co-founder Sergey Nazarov recently joined executives from JP Morgan and Amazon at the Federal Reserve Fintech Conference. The panel focused on the convergence of global payment systems and digital assets.  

NEW: CHAINLINK AT THE FEDERAL RESERVE

Just now, @SergeyNazarov joined key decision makers from J.P. Morgan & Amazon at the Federal Reserve Fintech Conference to discuss how global payment systems & digital assets are converging.

Full video ↓ pic.twitter.com/5r3d03Bt2v

— Chainlink (@chainlink) November 12, 2025
It signals that Chainlink’s interoperability solutions are gaining traction among major financial players. Such appearances at top-tier policy forums typically boost institutional trust and visibility, key catalysts for large-scale adoption.

Despite Positive News, LINK Holders Keep SellingNonetheless, even as Chainlink edges closer to ETF approval and institutional integration, on-chain data shows persistent selling among LINK holders.

Sponsored

Sponsored

10/10 REALLY fucked up $LINK. Things were in a good place otherwise before that event.

I think it will be ok but it might take longer than people think before we crawl out of this hole. pic.twitter.com/xDVeFa8icg

— CRP Survival Mode (@ChainlinkP) November 13, 2025
Based on the above post, sentiment mirrors a broader investor trend of disillusionment during accumulation phases. ClairHawk Capital explained that such patterns often accompany sideways, illogical, and bearish price action even when fundamentals are strong.

“They all do the same exact behavior when in accumulation…big money can’t just buy all at once and they also raise money by pumping distractions and memes and use that money to continue accumulating the asymmetric plays with the extra money as long as the public and retail are oblivious…once enough has accumulated, price action will start breaking out and enter price discovery,” the analyst explained.

Whales Accumulate as Exchange Balances Hit Record LowWhile retail investors appear cautious, whales are steadily accumulating. According to on-chain analyst Ali, large holders have added over 4 million LINK tokens in the past two weeks, which has pushed the Exchange Supply Ratio to its lowest level ever.

Sponsored

Sponsored

Arca Research also observed that LINK on exchanges [is] in freefall, reaching a 2+ year low. This suggests long-term holders are moving tokens off exchanges in anticipation of higher prices.

LINK Exchange Balance. Source: Arca on XWith the Bitwise Chainlink ETF now on the DTCC platform, Chainlink’s path toward mainstream exposure is clearer than ever. Institutional integration, combined with whale accumulation, could soon shift market sentiment.

Chainlink (LINK) Price Performance. Source: BeInCryptoAs of this writing, LINK token was trading for $15.93, up by almost 3% in the last 24 hours.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

On November 12, 2025, Bearing Point Capital, LLC disclosed a sale of 22,893 shares of Sprouts Farmers Market (SFM +5.25%), reducing its position by an estimated $4.7 million.

What happenedAccording to a filing with the Securities and Exchange Commission dated November 12, 2025, Bearing Point Capital sold 22,893 shares of Sprouts Farmers Market during the third quarter.

The position's value fell to $1.86 million from a level previously representing 1.2% of fund AUM.

Post-trade, SFM comprised 0.3% of the fund's $580.98 million in reportable assets.

What else to knowThe firm's SFM holding decreased and now represents 0.32% of Bearing Point's 13F AUM after the sale.

Bearing Point Capital's top holdings as of quarter-end: 

Nvidia (NVDA +0.33%): $35.5 million (6.1% of AUM)Apple (AAPL 0.65%): $23.5 million (4.1% of AUM)Microsoft (MSFT +0.48%): $18.3 million (3.1% of AUM)Alphabet (GOOGL 1.70%) (GOOG 1.48%): $15.6 million (2.7% of AUM)Broadcom (AVGO +0.93%): $14.9 million (2.6% of AUM)As of November 11, 2025, shares of Sprouts Farmers Market were priced at $78.02, down 47% over the past year, underperforming the S&P 500 by 60 percentage points.

Sprouts has grown sales by 6.5% annually over the last five years.

The company's shares remain 56% below their 52-week high.

Company overviewMetricValueRevenue (TTM)$8.65 billionNet income (TTM)$513.45 millionPrice (as of market close November 11, 2025)$78.02One-year price change(47%)Company snapshotSprouts Farmers Market:

Offers fresh, natural, and organic food products, including produce, meat, seafood, bakery, vitamins, and health-related items.Operates a grocery retail model, generating revenue through in-store sales across a broad assortment of perishable and non-perishable categories.Targets health-conscious consumers in the United States, with a focus on individuals seeking natural and organic food options.Sprouts Farmers Market is a leading U.S. specialty grocery retailer, operating hundreds of stores across 23 states.

The company differentiates itself through a focus on fresh, natural, and organic products, appealing to a growing segment of health-oriented shoppers.

Its scale and curated product mix position it competitively within the consumer defensive sector.

Foolish takeBearing Point Capital opened its position in Sprouts Farmers Market during the second quarter of 2025 at an average price of $165 per share.

Just one quarter later, the firm sold over half of its Sprouts shares at an average price of $109, taking a pretty hefty loss on its transactions.

While it's impossible to tell what exactly Bearing Point's reasoning for the quick change of heart is, Sprouts looks like an interesting "buy-the-dip" opportunity, in my Foolish opinion.

From the start of 2024 to early 2025, Sprouts' share price went from roughly $50 per share to $180. Similarly, its P/E ratio went from around 20 to nearly 50.

Following its recent 50% plunge from this all-time high share price, however, Sprouts is back to trading at a relatively cheap 16 times earnings.

Despite what this drop would imply, Sprouts just grew revenue, same-store sales, and earnings per share by 13%, 6%, and 34% in its latest quarter.

Sprouts is far from a "broken" stock.

Armed with consistent free cash flows, a new $1 billion share repurchase plan (versus a market cap of only $8 billion), and a tailwind from customers looking for healthier food options working in its favor, Sprouts Farmers Market looks like an exceptional "buy-the-dip" investment at today's reasonable valuation.

Glossary13F reportable assets: Assets that institutional investment managers must disclose quarterly to the Securities and Exchange Commission (SEC) on Form 13F.

Assets under management (AUM): The total market value of investments managed by a fund or investment firm.

Net position change: The difference in the number or value of shares held in a security after buying or selling.

Top holdings: The largest investments in the fund's portfolio, typically ranked by market value or portfolio weight.

Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.

Compound annual growth rate (CAGR): The annualized rate at which an investment grows over a specified period, assuming profits are reinvested.

Consumer defensive sector: Industry segment including companies that produce essential goods like food, beverages, and household products, less sensitive to economic cycles.

Campaign harnesses the power of sound to empower social media users to create a kinder algorithm and encourage more positive social spaces

OAKLAND, Calif.--(BUSINESS WIRE)--To celebrate World Kindness Day 2025, e.l.f. Beauty (NYSE: ELF) introduces “The Sound of Kindness,” a social-first campaign designed to help shift social algorithms toward positivity through the power of sound and create a movement of collective goodness. In partnership with Beekman 1802 and research and charitable partner Kindness.org, the initiative invites the community to break the cycle of doom scrolling and harness the evidence-based ability of sound to enhance well-being and inspire acts of kindness.i

To celebrate World Kindness Day 2025, e.l.f. Beauty introduces “The Sound of Kindness,” a social-first campaign designed to help shift social algorithms toward positivity through the power of sound and create a movement of collective goodness.

Share
Studies reviewed by Kindness.org reveal that “kindness is good for you,” showing that natural and prosocial audio can boost emotional wellness—lowering stress, enhancing mood, and encouraging prosocial behavior.ii Inspired by these insights, all of e.l.f. Beauty’s brands—e.l.f. Cosmetics, e.l.f. SKIN, Well People, Keys Soulcare, Naturium, and rhode—along with Beekman 1802 and Kindness.org, have created unique audiovisual stories designed to interrupt the content on users’ feeds. Each “Sound of Kindness” asset brings to life a thoughtfully curated soundscape, accompanied by a call to action to pay it forward and share these moments with others.

“Kindness isn’t just a feeling—it’s a force. It changes our chemistry, rewires our thinking, and strengthens our communities,” said Kory Marchisotto, Chief Marketing Officer of e.l.f. Beauty. “We created ‘The Sound of Kindness’ with Kindness.org and Beekman 1802 to highlight the power of force-multiplying with kindred spirits, aspiring to create an algorithm that is more positive, inclusive, and accessible. It’s a small ask with a big impact. For me, the sound of purring cats fuels me to make the world a better place—for every eye, lip, and face.”

Sound transforms everyday moments into cultural touchpoints that inspire connection, celebration and community. It serves as a data point for social platforms affecting discovery, engagement, and content tailored to users’ preferences, similar to hashtags and trends.

“Sound is such a core part of the TikTok experience, uniting a global community through creativity, expression, and joy. By engaging with sounds and songs, creators transform everyday moments into cultural touchpoints that inspire connection and celebration," said Sofia Hernandez, Global Head, Business Marketing & Commercial Partnerships, TikTok. "TikTok showcases the power of sound to bring people together worldwide."

A Symphony of Kindness

e.l.f. Cosmetics & e.l.f. SKIN a sound-driven ASMR experience that transforms product sounds into calming natural elements, inspiring mindfulness and relaxation.

Well People celebrates the sounds of a sunny meadow with birdsong and greenery, reflecting its commitment to e.l.f. clean, nature-inspired beauty.

Keys Soulcare offers a soothing sound bath of singing bowls and chimes, inviting a mindful pause through sound as a form of kindness and calm.

Naturium highlights the gentle, rhythmic sounds of face washing to evoke the soothing connection between self-kindness, consistency, and self-care.

rhode captures the tranquil sound of running water, pairing it with serene visuals of a bubble bath to evoke a peaceful self-care ritual.

Beekman 1802 spotlights the joyful bleats of baby goats at play, embodying the brand’s farm-to-skin heritage and spirit of neighborly kindness.

Kindness.org shares an instrumental “You Are My Sunshine” soundtrack over scenes of simple human connection, celebrating everyday acts of kindness.

“‘The Sound of Kindness’ brings our mission to life, translating what we know from science into an experience that reminds us how positive moments can shape emotion, behavior, and connection,” said Jaclyn Lindsey, Co-Founder and CEO of Kindness.org. “We are deeply grateful to e.l.f. Beauty, Beekman 1802, and all of the brands in this campaign for celebrating World Kindness Day in such a creative and meaningful way, turning insight into action and inspiring a ripple of kindness and connection around the world.”

Building on last year’s World Kindness Day collaboration, e.l.f. and Beekman 1802 are returning to Roblox with “The Sound of Kindness.” Players can explore an immersive world filled with kindness-inspired sounds, discover Beekman’s beloved baby goats hidden throughout the map, and welcome them to their own “Kind Farm.” Launching November 13, the experience blends beauty and play in a fun, unexpected way.

"At Beekman 1802, we always celebrate World Kindness Day as a key part of our holiday season. This year we wanted to make it the G.O.A.T. so, we turned to our neighbors at e.l.f. to help us shout it from the rooftops. When we all work together, we can put more kindness into the world. And who doesn't like the sound of that?” said Dr. Brent Ridge, Founder, Beekman 1802.

e.l.f. Beauty will also host a Twitch livestream on e.l.f. YOU! on November 13, at 4PM ET, featuring Beekman 1802 co-founder Dr. Brent Ridge, Chief Science Officer for kindness.org Dr Oliver Scott Curry and founder of the Sonic Institute Adrian DiMatteo, a sound therapist who will explore the science of sound and its impact on emotion, while creating an e.l.f. Beauty–inspired soundscape for the community to enjoy.

About e.l.f. Beauty

e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. The mission is clear: to make the best of beauty accessible to every eye, lip and face. e.l.f. Beauty and its brands, e.l.f. Cosmetics, e.l.f. SKIN, Keys Soulcare, Well People, Naturium and rhode, are led by purpose, driven by results and elevated by superpowers, offering e.l.f. clean and vegan products. e.l.f. Beauty proudly stands as the first beauty company with Fair Trade Certified™ facilities. With a kind heart at the center of e.l.f.’s ethos, the company donates at least 2% of the prior year’s profits to organizations that make positive impacts. Learn more at www.elfbeauty.com.

About Kindness.org

Kindness.org is the world's leading scientific authority on kindness. Our work is distinguished by its rigorous research and impact measurement, which examines how the practice of kindness can improve quality of life for ourselves and others. We use our findings to develop data-driven programs for schools, communities, and workplaces to educate and inspire people to choose kindness. This year, we are introducing the Kindness Quotient (KQ), a groundbreaking new tool designed to measure and strengthen kindness among coworkers, and partnering with Seesaw to bring our Learn Kind curriculum to more classrooms, empowering students and educators to create a culture of compassion and connection.

About Beekman 1802

Beekman 1802 is a skin health brand based on the clinical science of 2 ingredients: Goat milk and Kindness. Founded by Dr. Brent Ridge, a Harvard-trained longevity physician, and Josh Kilmer-Purcell, a bestselling author, the brand is a leading milk-based brand for sensitive skin. With its 31 active ingredients that strengthen the skin barrier and balance the microbiome, Beekman 1802 products are Clinically Kind® and proven to rebalance, rebuild, and repair even the most sensitive skin to its healthiest state.

i

Fan L, Baharum MR. The effect of exposure to natural sounds on stress reduction: a systematic review and meta-analysis. Stress. 2024 Dec 31;27(1):2402519.

Saskovets M, Saponkova I, Liang Z. Effects of Sound Interventions on the Mental Stress Response in Adults: Scoping Review. JMIR Ment Health. 2025 Mar 24;12:e69120.

Buxton RT, Pearson AL, Allou C, Fristrup K, Wittemyer G. A synthesis of health benefits of natural sounds and their distribution in national parks. Proc Natl Acad Sci. 2021 Apr 6;118(14):e2013097118.

Zhu R, Yuan L, Pan Y, Wang Y, Xiu D, Liu W. Effects of natural sound exposure on health recovery: A systematic review and meta-analysis. Sci Total Environ. 2024 Apr;921:171052.

Maltezou-Papastylianou C, Scherer R, Paulmann S. How do voice acoustics affect the perceived trustworthiness of a speaker? A systematic review. Front Psychol. 2025 Mar 10;16:1495456.

Pardo-Olmos M, Martí-Vilar M, Hidalgo-Fuentes S, Cabedo-Peris J. Interventions Through Music and Interpersonal Synchrony That Enhance Prosocial Behavior: A Systematic Review. Eur J Investig Health Psychol Educ. 2025 Feb 28;15(3):29.

ii

Raposa EB, Laws HB, Ansell EB. Prosocial Behavior Mitigates the Negative Effects of Stress in Everyday Life. Clin Psychol Sci J Assoc Psychol Sci. 2016 July;4(4):691–8.

Nelson-Coffey SK, Fritz MM, Lyubomirsky S, Cole SW. Kindness in the blood: A randomized controlled trial of the gene regulatory impact of prosocial behavior. Psychoneuroendocrinology. 2017 July;81:8–13.

Whillans AV, Dunn EW, Sandstrom GM, Dickerson SS, Madden KM. Is spending money on others good for your heart? Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2016 June;35(6):574–83.

Trew JL, Alden LE. Kindness reduces avoidance goals in socially anxious individuals. Motiv Emot. 2015 Dec 1;39(6):892–907.

More News From e.l.f. Beauty

U.S. firm GE Vernova and Germany's Siemens Energy are in talks to supply gas turbines to a $7 billion project aiming to rebuild Syria's war-damaged power sector, three people familiar with the matter told Reuters.

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST

Company Participants

Miranda Peto Benvenuti
Peter Altman - CEO, President & Director
David McClung - Chief Financial Officer

Conference Call Participants

Lander Egaña-Gorroño - H.C. Wainwright & Co, LLC, Research Division
James Molloy - Alliance Global Partners, Research Division
Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to the BioCardia Third Quarter Financial Results and Business Update Conference Call. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call.

I would now like to turn the call over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda.

Miranda Peto Benvenuti

Thank you. Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer; and David McClung, the company's Chief Financial Officer.

During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC on March 26, 2025, and in subsequently filed reports on Form 10-Q.

The content of this call contains time-sensitive information that is

Recommended For You

Ares Commercial Real Estate Corporation faces ongoing challenges with distressed loans and a shrinking portfolio, despite a high 11.9% dividend yield. ACRE trades at a 50% discount to tangible book value, but risks from maturing bank debt and low loan yields outweigh potential upside. The company's focus on portfolio stabilization and safer financing is critical, as further dividend cuts are likely if revenue continues to decline.

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $70.0 million aggregate principal amount of notes from Ionis. The sale of the notes is expected to close on November 17, 2025, subject to customary closing conditions.

The notes will be general unsecured obligations of Ionis, and will not bear regular interest and the principal amount of the notes will not accrete. The notes will mature on December 1, 2030, unless earlier converted, redeemed or repurchased.

Ionis estimates that the net proceeds from the offering will be approximately $682.8 million (or approximately $751.2 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by Ionis.

Ionis expects to use approximately $267.6 million of the net proceeds from the offering to repurchase for cash $200.0 million in aggregate principal amount of its 0% Convertible Senior Notes due 2026 (the “2026 notes”) pursuant to the concurrent note repurchase transactions described below. Ionis expects to use the remaining net proceeds from the offering for additional repurchases of the 2026 notes from time to time following the offering, including the repayment of any remaining 2026 notes at maturity, and for general corporate purposes.

Before September 1, 2030, holders will have the right to convert their notes only upon the satisfaction of specified conditions and during certain periods. On or after September 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes at any time. Upon conversion, Ionis will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The conversion rate for the notes will initially be 10.1932 shares of Ionis’ common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $98.10 per share of Ionis’ common stock). The initial conversion price represents a premium of approximately 35.0% over the last reported sale price of $72.67 per share of Ionis’ common stock on November 12, 2025. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued or unpaid special interest, if any.

Ionis may not redeem the notes prior to December 6, 2028. Ionis may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on a redemption date on or after December 6, 2028 if the last reported sale price of Ionis’ common stock has been at least 130% of the conversion price for the notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Ionis provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. However, Ionis may not redeem less than all of the outstanding notes unless at least $100.0 million aggregate principal amount of notes are outstanding and not called for redemption as of the time Ionis sends the related notice of redemption. No sinking fund is provided for the notes.

If Ionis undergoes a “fundamental change” (as defined in the indenture that will govern the notes), then, subject to certain conditions and limited exceptions, holders may require Ionis to repurchase for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or if Ionis delivers a notice of redemption, Ionis will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called) for redemption during the related redemption period (as defined in the indenture that will govern the notes), as the case may be.

Concurrently with the pricing of the notes in the offering, Ionis entered into separate and individually negotiated transactions with certain holders of the 2026 notes to repurchase for cash $200.00 million in aggregate principal amount of the 2026 notes on terms negotiated with each holder (each, a “concurrent note repurchase transaction”). This press release is not an offer to repurchase the 2026 notes, and the offering of the notes is not contingent upon the repurchase of any of the 2026 notes.

In connection with any repurchase of the 2026 notes, Ionis expects that holders of the 2026 notes who agree to have their 2026 notes repurchased and who have hedged their equity price risk with respect to such notes (the “hedged holders”) will unwind all or part of their hedge positions by purchasing Ionis’ common stock and/or entering into or unwinding various derivative transactions with respect to Ionis’ common stock. The amount of Ionis’ common stock to be purchased by the hedged holders or in connection with such derivative transactions may be substantial in relation to the historic average daily trading volume of Ionis’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of Ionis’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. Ionis cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or Ionis’ common stock.

The notes and any shares of Ionis’ common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Ionis' Forward-looking Statement

This press release includes forward-looking statements regarding the offering, including statements regarding the anticipated completion and timing of the offering, the expected repurchase of 2026 notes, including the concurrent note repurchase transactions, the expected unwind by the hedged holders of their hedge positions and the anticipated effects of such actions, and Ionis’ expected use of proceeds from the offering. Any statement describing Ionis’ expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including, without limitation, changes in market conditions, whether Ionis will be able to satisfy closing conditions related to the offering, whether and on what terms Ionis may repurchase or repay any of the 2026 notes, the concurrent note repurchase transactions, the actions of the hedged holders and unanticipated uses of capital. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2024 and most recent Form 10-Q, which are on file with the Securities and Exchange Commission, as well as other subsequent filings Ionis makes with the Securities and Exchange Commission from time to time. Copies of these and other documents are available from Ionis.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc.

More News From Ionis Pharmaceuticals, Inc.

Company announcement – No. 23 / 2025

Zealand Pharma Announces Financial Results for the First Nine Months of 2025
With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026.

Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline data in H1 2026.Approaching Phase 3 data in H1 2026 with survodutide, following last participant last visit in the 76-week SYNCHRONIZETM-1 trial in people with overweight and obesity without type 2 diabetes.Zealand Pharma is excited to outline a catalyst-rich 2026 at its upcoming Capital Markets Day on December 11, highlighting its ambition to become a generational biotech company driving the next wave of innovation in obesity. Copenhagen, Denmark, November 13, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the nine months ended September 30, 2025, and provided a corporate update.

Ready for key near-term data catalysts and driving the next wave of innovation
Adam Steensberg, President and Chief Executive Officer at Zealand Pharma said:
“I am highly encouraged by the strong execution across our clinical programs and the momentum behind our partnership with Roche. As we enter a catalyst-rich period for the company, I look forward to our Capital Markets Day in December, where we will set the stage for the rapidly approaching Phase 2 and 3 data readouts for petrelintide and survodutide. We will also share more about our ambitious research strategy that builds on Zealand Pharma’s unique expertise in peptide R&D and our strong foundation to lead the next wave of innovation in obesity”.

Key financial results for Q3 2025 year-to-date

DKK millionQ3-25
YTDQ3-24
YTDRevenue9,14654Net operating expenses1-1,4792-919Operating result7,6662-873Net financial items-6281 DKK millionSep-30,
2025Dec-31,
2024Cash position316,1699,022 Notes:
1. Net operating expenses consist of R&D, S&M, G&A and Other operating items.
2. Excluding transaction-related costs of DKK 196 million related to the Roche partnership agreement. Operating expenses including transaction fees for the period amount to DKK 1,675 million.
3. Cash position includes cash, cash equivalents and marketable securities.

Highlights in the third quarter of 2025
Obesity

Petrelintide, amylin analog. Reached a key milestone in the petrelintide monotherapy program with the completion of the 28-week primary endpoint visit for the last participant in the Phase 2 ZUPREME-1 trial in people with overweight and obesity. Chronic inflammation

ZP9830, Kv1.3 Ion Channel Blocker. In September 2025, the last participant was enrolled and randomized in the first-in-human single ascending dose clinical trial of ZP9830.
Events after the reporting date
Obesity

Petrelintide, amylin analog. In November 2025, enrollment of all trial participants has been completed in ZUPREME-2, the Phase 2 trial evaluating petrelintide versus placebo in people with overweight or obesity and type 2 diabetes.Survodutide, glucagon/GLP-1 receptor dual agonist. In October 2025, the last participant in the Phase 3 SYNCHRONIZETM-1 trial in people with overweight and obesity without type 2 diabetes completed the 76-week primary endpoint visit. Baseline characteristics for SYNCHRONIZETM-1 and SYNCHRONIZETM-2 were presented at the Obesity Society Annual Meeting (ObesityWeek) in Atlanta, U.S., in November 2025.Dapiglutide, GLP-1/GLP-2 receptor dual agonist. Development of dapiglutide has been paused as part of active portfolio management, focusing investments on programs with the greatest potential for clinical differentiation and long-term value creation.
Upcoming events next 12 months
Obesity

Petrelintide, amylin analog. In the first half of 2026, Zealand Pharma expects to report topline results from the 42-week Phase 2 ZUPREME-1 trial. In the second half of 2026, Zealand Pharma and Roche expect to initiate a Phase 3 program with petrelintide monotherapy. Petrelintide, amylin analog. In the second half of 2026, Zealand Pharma expects to report topline results from the Phase 2 ZUPREME-2 trial in people with overweight or obesity and type 2 diabetes. Petrelintide/CT-388, amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate Phase 2 with petrelintide/CT-388 in the first half of 2026. Survodutide, glucagon/GLP-1 receptor dual agonist. Topline results from SYNCHRONIZETM-1 and SYNCHRONIZETM-2, the Phase 3 trials with survodutide in people with overweight and obesity without and with type 2 diabetes, respectively, are expected in the first half of 2026. Rare diseases

Glepaglutide in SBS. In the fourth quarter of 2025, Zealand Pharma expects to initiate a Phase 3 clinical trial of glepaglutide (EASE-5) that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S. Glepaglutide in SBS. The company expects potential regulatory approval in the EU in the first half of 2026. In parallel, the company is engaging in partnership discussions for future commercialization. Dasiglucagon in CHI. The ability of Zealand Pharma to resubmit the New Drug Application for dasiglucagon for the treatment of congenital hyperinsulinism is contingent on an inspection classification upgrade of a third-party manufacturing facility. Zealand Pharma has implemented a supply contingency plan that includes the qualification of an alternative supplier to ensure that the product can be made available to patients in need as quickly as possible. Chronic inflammation

ZP9830, Kv1.3 Ion Channel Blocker. Zealand Pharma expects to report topline data from the first-in-human single ascending dose clinical trial with ZP9830 in the first half of 2026. Corporate

Zealand Pharma Capital Markets Day. Zealand Pharma will host a Capital Markets Day in London on December 11, 2025. Speakers will include members of Management as well as external experts and thought leaders in obesity. The event will set the stage for the rapidly approaching Phase 2 and Phase 3 data readouts with petrelintide and survodutide, which have the potential to redefine the near-term future of weight management. Zealand Pharma will also share insights into the company’s ambitious research strategy aimed at leading the next wave of innovation. Financial guidance for 2025

The financial guidance, originally issued on February 20, 2025, has been narrowed from previously DKK 2.0-2.5 billion. Net operating expenses excluding Other operating items are now expected to be between DKK 2.0-2.3 billion, reflecting the decision to pause the development of dapiglutide, previously planned to advance to Phase 2b development in 2025. DKK millionUpdated
guidance
Nov 13, 20254,5Previous
guidance
Feb 20, 20254Revenue anticipated from existing and new license and partnership agreementsNo guidanceNo guidanceNet operating expenses2,000-2,3002,000-2,500 Notes:
4. Net operating expenses consists of R&D, S&M, and G&A, and excludes Other operating items.
5. Financial guidance based on foreign exchange rates as of November 12, 2025.

Conference call today at 2 PM CET / 8 AM ET
Zealand Pharma’s management will host a conference call today at 2:00 PM CET / 8:00 AM ET to present results through the first nine months of 2025 followed by a Q&A session. Participating in the call will be Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The conference call will be conducted in English.

To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI7925746c60164cb2a799f2cd553ae1ae. The live listen-only audio webcast of the call and accompanying slides presentation will be accessible at https://edge.media-server.com/mmc/p/96oja22m.  Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/.

Financial Calendar for 2025

Q4/FY 2025February 19, 2026
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.

Forward-looking Statements
This company announcement contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development, and commercialization of pharmaceutical products, the timing of the company’s clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2025 and financial guidance for 2025. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”, and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release/company announcement and are based on information available to Zealand Pharma as of the date of this release/announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
Zealand Pharma® is a registered trademark of Zealand Pharma A/S.

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: [email protected]

Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: [email protected]

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
Email: [email protected]

Zealand Pharma Q3 2025 Interim Report

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025. “This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval.

Xero Limited (OTCPK:XROLF) Q2 2026 Earnings Call November 12, 2025 6:30 PM EST

Company Participants

Sukhinder Cassidy - Chief Executive Officer
Claire Bramley - Chief Financial Officer

Conference Call Participants

Eric Choi - Barrenjoey Markets Pty Limited, Research Division
Bob Chen - JPMorgan Chase & Co, Research Division
Garry Sherriff - RBC Capital Markets, Research Division
Kane Hannan - Goldman Sachs Group, Inc., Research Division
Roger Samuel - Jefferies LLC, Research Division
Rohan Sundram - MST Financial Services Pty Limited, Research Division
Nicholas Basile - CLSA Limited, Research Division
Siraj Ahmed - Citigroup Inc., Research Division
Paul Mason - E&P, Research Division
Andrew Gillies - Macquarie Research
Lucy Huang - UBS Investment Bank, Research Division
Sriharsh Singh - BofA Securities, Research Division

Presentation

Operator

Thank you for standing by, and welcome to the Xero Limited 2026 Interim Results Conference Call. I am joined by Xero's Chief Executive Officer, Sukhinder Singh Cassidy; and Chief Financial Officer, Claire Bramley. [Operator Instructions]

I would now like to hand the call over to Sukhinder Singh Cassidy, Chief Executive Officer of Xero. Please go ahead.

Sukhinder Cassidy
Chief Executive Officer

Good morning from Sydney, Australia. Thank you for joining our investor briefing today covering Xero's financial and operating results for the half year ending September 30, 2025. I'm Sukhinder Singh Cassidy and I'm with Claire Bramley, our CFO.

Our first agenda item is the summary of Xero's performance for the half year. I'll then pass to Claire to cover our financial results in more detail before I finish with strategic priorities and Xero's outlook. After that, we'll move to Q&A.

So moving to a summary of our results on Slide 5. We are very pleased with our H1 fiscal '26-year results, which clearly demonstrates our sustained revenue momentum and execution against our strategy. We continue to achieve strong revenue growth across our 3x3 portfolio. This, along with another meaningful increase in

Recommended For You

RiverNorth/DoubleLine Strategic Opportunity Fund is downgraded to a sell due to limited growth prospects in a high-rate environment. OPP offers a high 14% dividend yield and trades at an 8.85% discount to NAV, but payout sustainability remains questionable. The fund's aggressive leverage and reliance on positive market momentum amplify risk, especially as interest rates remain elevated.

VICTORIA, Seychelles, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange (UEX), has announced the official addition of LLYUSDT, MAUSDT, UNHUSDT stock index perpetual futures, expanding its range of Real World Asset (RWA) products for global traders. Bitget users can access these contracts with leverage of up to 10x.

The perpetual futures contracts are settled in USDT, with a tick size of 0.01 and isolated margin mode. They operate on a 24/5 schedule, trading from Monday 12:00 AM to Saturday 12:00 AM (UTC-4), with hourly funding fee settlements. While trading is available throughout the week, contracts will be closed during public holidays when underlying markets are inactive, ensuring fair price alignment with traditional markets.

This new Stock Futures Index Futures allows traders to gain onchain exposure to some of the world’s largest companies such as, Eli Lilly And Co, Montage Gold Corp, UnitedHealth Group Inc, all while leveraging the flexibility of crypto derivatives. Bitget’s stock futures segment recently surpassed $3 billion in cumulative trading volume, showing the growing demand for tokenized equity and institutional-grade products.

This new milestone comes in quick succession as Bitget hit $1 billion in cummulative trading volume two weeks ago. Bitget then launched a limited-time 90% trading fee reduction campaign across all stock futures contracts. Running until January 31, the campaign allows both new and existing users to enjoy ultra-low trading fees while exploring the expanding universe of tokenized stock futures. The initiative reflects Bitget’s goal of making traditional market access more affordable and frictionless through blockchain infrastructure.

Bitget continues to prioritize transparency, security, and product innovation across its derivatives ecosystem. While Stock Index Perpetual Futures are currently not supported on Unified Account trading, the exchange will continue to evaluate upgrades based on user demand and evolving market conditions. By combining the accessibility of crypto derivatives with traditional market exposure, Bitget continues to expand its UEX model, bridging digital assets with global equities and enabling a wider range of strategies for all traders.

For full details, users can visit here.

About Bitget

Established in 2018, Bitget is the world's largest Universal Exchange (UEX), serving over 120 million users with access to millions of crypto tokens, tokenized stocks, ETFs, and other real-world assets on a single platform. The ecosystem is committed to helping users trade smarter with its AI-powered trading tools, interoperability across tokens on Bitcoin, Ethereum, Solana, and BNB Chain, and wider access to real-world assets. On the decentralized side, Bitget Wallet runs as the leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built-in the platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d08afe61-e602-41b7-8dc2-ed65eb39132b

Draganfly Inc. (DPRO) Q3 2025 Earnings Call November 12, 2025 5:30 PM EST

Company Participants

Rolly Bustos
Cameron Chell - President, CEO & Director
Paul Sun - Chief Financial Officer

Presentation

Rolly Bustos

All right. To respect everybody's time, I think we will get going right away. So again, greetings, and welcome to all the shareholders and stakeholders for joining us today for the Draganfly 2025 Q3 Earnings Call. My name is Rolly Bustos, and I am the Internal Investor Relations representative here at Draganfly. We appreciate you joining us.

As always, we'll start with our CEO and President, Cameron Chell, recapping the third quarter earnings highlights. Next will be a more detailed financial review with our CFO, Paul Sun. We will conclude, as always, by addressing the pre-submitted questions we have received. You are welcome to reach out to me any time at [email protected], if you have further questions.

I remind everyone that this presentation may include forward-looking information and statements. These statements are not guarantees of future performance or financial results and undue reliance should not be placed on them. Any future events or financial results may differ from what might be discussed here.

The company's results and statements are accurate as of today, November 12, 2025. We're under no obligation to update or renew these statements outside of material press release disclosure going forward. The full forward-looking disclaimer can be found on the screen right now. So Cam, if you're ready, please go ahead.

Cameron Chell
President, CEO & Director

Sounds great. Thanks, Rolly. Really appreciate that. And thank you, everybody, for taking the time to be with us today. We really deeply appreciate your time and consideration. So maybe just to hit the highlights out of the gate. So our revenue for Q3 2025 was $2.155 million, an increase of 14.4% year-over-year, that includes $1.6 million of product sales and about $530,000

Recommended For You

The industrial conglomerate said it assumes the global economic environment will stabilize, and targets comparable revenue growth in the range of 6% to 8% for fiscal 2026.

US President Donald Trump has officially signed a bill ending the longest-ever US government shutdown. Bitcoin (ETH), Ethereum (ETH), XRP, and the broader crypto market saw a slight bounce.

TLDR:

Bitcoin holds steady above $100K despite $2.7B ETF outflows this month.
ETF outflows account for just 1.5% of total Bitcoin ETF assets.
Analysts note price resilience may signal short-term accumulation.
Traders eye possible $150K target if bullish structure continues.

Bitcoin has maintained its position above the $100,000 mark despite ongoing ETF outflows. 

At press time, data from CoinGecko shows BTC trading at $102,321, down 0.91% in the last 24 hours. Over the past week, the asset has declined by just 0.98%, signaling resilience amid selling pressure. 

Analysts note that the recent stall in outflows could shape the next directional move for the cryptocurrency.

ETF Flows Reflect Cautious Market Behavior
According to data shared by Bloomberg’s Eric Balchunas, Bitcoin ETFs have seen $2.7 billion in outflows over the past month. 

He noted that this represents about 1.5% of total assets, meaning 98.5% of funds remain invested. The data suggests investors are reducing exposure but not exiting the market entirely. This pattern indicates a measured sentiment rather than a wholesale retreat.

About $2.7b has come out of the bitcoin ETFs in the past month, new chart from @JSeyff puts it into context, and shows the two steps fwd one step back pattern, it represents just 1.5% of total assets = 98.5% of aum hanging tough. pic.twitter.com/pNlhD6pMcZ

— Eric Balchunas (@EricBalchunas) November 11, 2025

Crypto trader Daan Crypto Trades observed that ETF flow patterns often act as short-term sentiment indicators. He noted that when large outflows occur without a price drop, the market may be forming a short-term base. 

Conversely, when inflows fail to push prices higher, it can mark a local top. The analyst emphasized that watching price reaction to ETF movements provides valuable context in ongoing cycles.

Bitcoin’s current position mirrors these dynamics. Despite notable outflows and fading sentiment, the price has held firm near $100K. Market participants view this consolidation as a potential sign of absorption before the next decisive move.

Source: Daan/x
Traders Debate Next Move Toward or Away From $150K
Market analyst HovWaves shared an alternative bullish outlook, suggesting Bitcoin may be setting up for an extended fifth wave higher. 

His chart analysis points to a possible BTC surge toward the $150K region once the current correction phase concludes. However, he added that a deeper pullback could occur if the market confirms a local top.

In a bearish scenario, a retracement to $69K, or even near $40K, remains possible, consistent with Bitcoin’s historical drawdowns. Yet traders emphasize that holding above the six-figure mark indicates sustained institutional support despite temporary ETF outflows.

$BTC

I forgot to get this alt bullish BTC count posted for you guys from last week(threaded)

The alt bullish count is that we're ramping up for an extended 5th

Currently working on Wave 2 of 5

That would carry prices much higher before this run is over

My primary though is… pic.twitter.com/IFqRo3RkwF

— Hov (@HovWaves) November 12, 2025

Price data from CoinGecko shows steady volume at $70.1 billion, underlining continued trading activity. As market flows stabilize, investors are closely watching whether Bitcoin can reclaim momentum or remain range-bound through November.